The inspection was conducted from 15th April, 2024 to 19th April, 2024. The said inspection was closed with zero 483 observations.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies.

The company?s consolidated net profit dropped 88.6% to Rs 23.14 crore on 22.65% decrease in revenue from operations to Rs 1,544.82 crore in Q3 FY24 over Q3 FY23.

The scrip fell 1.26% to end at Rs 426.25 on Friday, 19 April 2024.

Powered by Capital Market - Live News